ARS Pharmaceuticals, Inc.
General ticker "SPRY" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
ARS Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -5.1%.
Estimated limits based on current volatility of 3.2%: low 10.08$, high 10.74$
Factors to consider:
- Total employees count: 90 as of 2021
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.10$, 13.74$]
- 2025-12-31 to 2026-12-31 estimated range: [3.68$, 10.38$]
Financial Metrics affecting the SPRY estimates:
- Positive: with PPE of 137.8 at the end of fiscal year the price was very low
- Positive: -3.60 < Operating profit margin, % of -3.34
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: Operating cash flow per share per price, % of 1.27 <= 6.82
- Positive: Shareholder equity ratio, % of 73.13 > 63.39
- Negative: Inventory ratio change, % of 4.96 > 0.84
Short-term SPRY quotes
Long-term SPRY plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1.32MM | $0.03MM | $89.15MM |
| Operating Expenses | $36.83MM | $67.55MM | $92.23MM |
| Operating Income | $-35.52MM | $-67.52MM | $-3.08MM |
| Non-Operating Income | $0.83MM | $13.15MM | $11.37MM |
| R&D Expense | $18.38MM | $20.27MM | $19.58MM |
| Income(Loss) | $-34.68MM | $-54.37MM | $8.29MM |
| Taxes | $0.00MM | $0.00MM | $0.29MM |
| Profit(Loss)* | $-34.68MM | $-54.37MM | $8.00MM |
| Stockholders Equity | $272.89MM | $230.76MM | $256.80MM |
| Inventory | $0.00MM | $0.00MM | $5.21MM |
| Assets | $281.44MM | $233.19MM | $351.15MM |
| Operating Cash Flow | $-40.08MM | $-59.27MM | $13.55MM |
| Capital expenditure | $0.20MM | $0.17MM | $0.56MM |
| Investing Cash Flow | $-0.20MM | $-87.18MM | $-106.10MM |
| Financing Cash Flow | $190.73MM | $6.90MM | $72.40MM |
| Earnings Per Share** | $-0.87 | $-0.57 | $0.08 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.